Abstract
The adoptive transfer of chimeric antigen receptor T cells (CAR-T cells) has demonstrated impressive clinical benefits in patients with hematological malignancies, however, no equivalent successes have been observed yet in solid tumors. The unsatisfactory outcome with solid tumors could be partly attributed to the lack of appropriate tumor-specific antigens. Here, we describe a novel strategy of tumor retargeting universal chimeric antigen receptor T cell therapy (TRUE-CAR T).
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
